Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GlycoMimetics, Inc.    GLYC

GLYCOMIMETICS, INC.

(GLYC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/19/2021 Date
3.75(c) 3.72(c) 3.76(c) 3.85(c) 3.81 Last
735 411 406 123 636 760 810 430 357 414 Volume
0.00% -0.80% +1.08% +2.39% -1.04% Change
More quotes
Financials (USD)
Sales 2020 8,40 M - -
Net income 2020 -50,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,49x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -64,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,98x
Yield 2021 -
Capitalization 184 M 184 M -
Capi. / Sales 2020 21,9x
Capi. / Sales 2021 -
Nbr of Employees 57
Free-Float 97,8%
More Financials
Company
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to... 
More about the company
Notations Surperformance© of GlycoMimetics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about GLYCOMIMETICS, INC.
01/07GLYCOMIMETICS : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator..
MT
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
AQ
2020GLYCOMIMETICS INC : Results of Operations and Financial Condition, Financial Sta..
AQ
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
BU
2020GLYCOMIMETICS : 3Q Earnings Snapshot
AQ
2020GLYCOMIMETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
2020GLYCOMIMETICS : Program Data to be Highlighted Via Three Oral Presentations and ..
BU
2020GLYCOMIMETICS : to Report Third Quarter Financial Results on November 6, 2020
AQ
2020GLYCOMIMETICS : to Report Third Quarter Financial Results on November 6, 2020
BU
More news
News in other languages on GLYCOMIMETICS, INC.
2017Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on GLYCOMIMETICS, INC.
More recommendations
Chart GLYCOMIMETICS, INC.
Duration : Period :
GlycoMimetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLYCOMIMETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 10,50 $
Last Close Price 3,85 $
Spread / Highest target 290%
Spread / Average Target 173%
Spread / Lowest Target -22,1%
EPS Revisions
Managers and Directors
NameTitle
Rachel K. King President, Chief Executive Officer & Director
Timothy R. Pearson Chairman
Brian M. Hahn Chief Financial Officer & Senior Vice President
John L. Magnani Chief Scientific Officer & Senior VP-Research
Helen M. Thackray Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GLYCOMIMETICS, INC.2.39%184
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.6.59%53 924
BEIGENE, LTD.33.52%31 458